Cerus Corporation CERS
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- +10.68%
- 1 year
- +62.86%
- Open
- 2.41
- Prev close
- 2.44
- Mkt cap
- 459.48M
- Vol
- 1.50M
- Avg vol
- 2.12M
- EPS
- -0.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.26
- High
- 2.41
- Forward P/E
- -22.57
- Beta
- 1.20
- Short ratio
- 4.10
- Inst. own
- 79.22%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.74
- 200-d avg
- 1.88
- 1y target
- 3.90
3M chart
Signals (20)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| RSI: Oversold | Jul 31, 2026 | 3 months ago |
Key statistics
- Market cap
- 293.43M
- Enterprise value
- 316.56M
- Trailing P/E
- 0.00
- Forward P/E
- -22.57
- PEG ratio
- 0.00
- Price / sales
- 1.67
- Price / book
- 5.49
- EPS (TTM)
- -0.11
- Beta
- 1.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -11.19%
- Revenue (TTM)
- 176.23M
- Revenue growth
- 15.70%
- Free cash flow
- -9.08M
- Total cash
- 75.56M
- Total debt
- 97.90M
- Return on equity
- -38.31%
- Shares outstanding
- 185.72M
- Short % of float
- 4.76%
- 50-day average
- 1.74
- 200-day average
- 1.88
Analyst view
Consensus: none
- Target (low)
- 2.50
- Target (mean)
- 3.90
- Target (high)
- 5.00
- Strong buy0
- Buy4
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.0125.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | -0.03 | -0.02 | +0.01 | +33.33% |
| Aug 1, 2024 | Jun 1, 2024 | -0.04 | -0.03 | +0.01 | +25.00% |
| May 2, 2024 | Mar 1, 2024 | -0.04 | -0.05 | -0.01 | -25.00% |
| Mar 5, 2024 | Dec 1, 2023 | -0.01 | -0.01 | 0.00 | 0.00% |
| Nov 2, 2023 | Sep 1, 2023 | -0.05 | -0.03 | +0.02 | +40.00% |
| Aug 2, 2023 | Jun 1, 2023 | -0.05 | -0.07 | -0.02 | -40.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 17, 2024 | Stifel | main | Buy | Buy |
| May 3, 2024 | Cantor Fitzgerald | main | Overweight | Overweight |
| Apr 12, 2024 | Craig-Hallum | init | — | Buy |
| Mar 7, 2024 | Stephens & Co. | reit | Equal-Weight | Equal-Weight |
| Mar 6, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Jan 20, 2023 | BTIG | down | Buy | Neutral |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- cerus.com
News
- Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Cerus Q2 EPS $(0.01), Inline, Sales $57.441M Miss $60.933M Estimate
- Cerus Raises FY2026 Sales Guidance from $227.000M-$231.000M to $229.000M-$231.000M vs $245.200M Est
- Cerus Announces William Greenman Ceases As President And CEO, Becomes Executive Chairman Effective July 1, 2026
- Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock
- Top 2 Health Care Stocks That May Plunge This Month
- Top 3 Health Care Stocks That May Collapse This Month
- This Caterpillar Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
Your note
Sign in to keep a note on CERS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENJAMIN RICHARD J. | Officer | Sale | Aug 1, 2024 | 438,007 |
| BJERKHOLT ERIC H | Director | Sale | Dec 11, 2024 | 162,133 |
| GREEN KEVIN DENNIS | Chief Financial Officer | Sale | Sep 3, 2024 | 536,093 |
| GREGORY DEAN A. | Director | Stock Award(Grant) | Jun 30, 2024 | 60,000 |
| JENSEN CHRYSTAL MENARD | Officer | Sale | Dec 15, 2024 | 457,578 |
| MOORE TIMOTHY L. | Director | Stock Award(Grant) | Jun 4, 2024 | 145,073 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 10.49% | 19,477,339 | 30.77M | Sep 29, 2024 |
| ARK Investment Management, LLC | 9.81% | 18,225,031 | 28.80M | Sep 29, 2024 |
| Blackrock Inc. | 7.90% | 14,669,054 | 23.18M | Sep 29, 2024 |
| Vanguard Group Inc | 5.84% | 10,848,098 | 17.14M | Sep 29, 2024 |
| Primecap Management Company | 4.60% | 8,544,000 | 13.50M | Sep 29, 2024 |
| Wasatch Advisors LP | 3.94% | 7,325,834 | 11.57M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Innovation ETF | 6.96% | 12,931,823 | 20.43M | Oct 30, 2024 |
| Primecap Odyssey Aggressive Growth Fund | 4.60% | 8,544,000 | 13.50M | Sep 29, 2024 |
| ARK ETF Tr-ARK Genomic Revolution ETF | 4.42% | 8,208,021 | 12.97M | Oct 30, 2024 |
| Wasatch Ultra Growth Fund | 3.69% | 6,849,908 | 10.82M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.98% | 5,535,900 | 8.75M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.50% | 4,644,437 | 7.34M | Oct 30, 2024 |